Multi-target Mechanism of Action of Curcumin in Rheumatoid Arthritis and Clinical Application

Authors

  • Lingxuan Dai
  • Yike Wang
  • Yinuo Wang

DOI:

https://doi.org/10.61173/cdhmm835

Keywords:

Rheumatoid arthritis, Curcumin, Multi-target mechanism, Inflammatory pathways, Osteoclast inhibition

Abstract

Rheumatoid arthritis (RA) has become a common disease that poses a significant threat to human health, and its conventional therapeutic approaches exhibit certain limitations. In recent years, increasing attention has been directed toward the clinical application and underlying mechanisms of Curcumin in the treatment of RA. This article presents a literature review that systematically summarizes the pathogenesis of RA, the pharmacological properties of curcumin, its mechanisms of action in RA, as well as relevant clinical studies and their application within the framework of traditional Chinese medicine (TCM) syndrome differentiation. Existing evidence suggests that curcumin can effectively alleviate clinical symptoms in patients with RA and improve overall therapeutic outcomes. Its core mechanisms are primarily associated with the modulation of anti-inflammatory pathways. Meanwhile, the majority of studies have validated its role as a foundational therapeutic agent. In conclusion, curcumin demonstrates a certain degree of feasibility in the treatment of RA; however, further high-quality clinical trials are required to verify its safety and to strengthen the evidence base for its clinical feasibility.

References

[1] Armstrong A P, Tometsko M E, Glaccum M, et al. RANK/ TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function[J]. Journal of Biological Chemistry, 2002, 277(46): 44347-44356.

[2] David J P, Sabapathy K, Hoffmann O, et al. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylationdependent and -independent mechanisms[J]. Journal of Cell Science, 2002, 115: 4317-4325.

[3] Karin M, Cao Y, Greten F R, et al. NF-kappaB in cancer: from innocent bystander to major culprit[J]. Nature Reviews Cancer, 2002, 2(4): 301-310.

[4] Maruyama T, Fukushima H, Nakao K, et al. Processing of the NF-kappa B2 precursor p100 to p52 is critical for RANKL- induced osteoclast differentiation[J]. Journal of Bone and Mineral Research, 2010, 25(5): 1058-1067.

[5] Ke D, Xu H, Han J, et al. Curcumin suppresses RANKL- induced osteoclast precursor autophagy in osteoclastogenesis by inhibiting RANK signaling and downstream JNK-BCL2-Beclin1 pathway[J]. Biomedical Journal, 2024, 47(1): 100605.

[6] Xu Z H, Shang W, Guo J H, et al. Curcumin reduces osteoclast generation in rheumatoid arthritis by inhibiting NF- κB signaling activation[J]. Chinese Journal of Osteoporosis and Bone Mineral Disorders, 2018, 11(2): 180-185.

[7] Xu Y Q, Zhang Y. Research progress of curcumin in the treatment of rheumatoid arthritis[J]. China Pharmaceutical Industry, 2023, 32(22): 154-158.

[8] Wang X Q, Wang T T, Fang X X, et al. Intervention of tyrosine hydroxylase expression alters joint inflammation and Th17/Treg imbalance in collagen-induced arthritis[J]. NeuroSignals, 2021, 29(1): 1-13.

[9] Liu Z Y, Zhe A C. Regulatory effect of curcumin on Th17/ Treg cell balance in patients with rheumatoid arthritis[J]. Journal of Wuhan University (Medical Sciences), 2022, 43(6): 917-920.

[10] Amalraj A, Varma K, Jacob J, et al. A novel highly bioavailable curcumin formulation improves symptoms and diagnostic indicators in rheumatoid arthritis patients: a randomized, double-blind, placebo-controlled, two-dose, threearm, parallel-group study[J]. Journal of Medicinal Food, 2017, 20(10): 1022-1030.

[11] Bagherniya M, Darand M, Askari G, et al. The clinical use of curcumin for the treatment of rheumatoid arthritis: a systematic review of clinical trials[J]. Advances in Experimental Medicine and Biology, 2021, 1291: 251-263.

Downloads

Published

2026-06-24